See more : GOAT Industries Ltd. (BGTTF) Income Statement Analysis – Financial Results
Complete financial analysis of Catalent, Inc. (CTLT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Catalent, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- BillerudKorsnäs AB (publ) (BILL.ST) Income Statement Analysis – Financial Results
- Coloured Ties Capital Inc. (TIE.V) Income Statement Analysis – Financial Results
- Ningbo Homelink Eco-iTech Co., Ltd. (301193.SZ) Income Statement Analysis – Financial Results
- Xi’an Catering Co., Ltd. (000721.SZ) Income Statement Analysis – Financial Results
- Toyota Motor Corp (TOM.SG) Income Statement Analysis – Financial Results
Catalent, Inc. (CTLT)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.catalent.com
About Catalent, Inc.
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.
Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 4.38B | 4.28B | 4.83B | 4.00B | 3.09B | 2.52B | 2.46B | 2.08B | 1.85B | 1.83B | 1.83B | 1.80B | 1.69B | 1.53B |
Cost of Revenue | 3.43B | 3.22B | 3.19B | 2.65B | 2.11B | 1.71B | 1.71B | 1.42B | 1.26B | 1.22B | 1.23B | 1.23B | 1.14B | 1.03B |
Gross Profit | 953.00M | 1.06B | 1.64B | 1.35B | 983.30M | 805.10M | 752.60M | 654.60M | 587.60M | 615.30M | 598.60M | 568.60M | 558.60M | 502.10M |
Gross Profit Ratio | 21.75% | 24.79% | 33.97% | 33.82% | 31.78% | 31.97% | 30.55% | 31.54% | 31.79% | 33.61% | 32.75% | 31.58% | 32.96% | 32.78% |
Research & Development | 0.00 | 18.00M | 23.00M | 21.00M | 63.80M | 54.50M | 52.50M | 52.80M | 55.00M | 53.50M | 51.50M | 49.50M | 0.00 | 0.00 |
General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 462.60M | 402.60M | 358.10M | 337.30M | 334.80M | 340.60M | 339.30M | 299.90M |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 935.00M | 831.00M | 844.00M | 687.00M | 577.90M | 512.00M | 462.60M | 402.60M | 358.10M | 337.30M | 334.80M | 340.60M | 339.30M | 299.90M |
Other Expenses | 767.00M | 6.00M | 41.00M | 19.00M | -7.90M | -2.70M | -7.70M | -8.50M | 15.60M | -42.40M | -10.40M | -25.10M | 3.80M | -26.00M |
Operating Expenses | 1.70B | 987.00M | 885.00M | 706.00M | 577.90M | 512.00M | 462.60M | 402.60M | 358.10M | 337.30M | 334.80M | 340.60M | 339.30M | 299.90M |
Cost & Expenses | 5.13B | 4.20B | 4.07B | 3.35B | 2.69B | 2.22B | 2.17B | 1.82B | 1.62B | 1.55B | 1.56B | 1.57B | 1.48B | 1.33B |
Interest Income | 0.00 | 184.00M | 123.00M | 110.00M | 126.00M | 111.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 254.00M | 184.00M | 123.00M | 110.00M | 126.10M | 110.90M | 111.40M | 90.10M | 88.50M | 105.00M | 163.10M | 203.20M | 183.20M | 165.50M |
Depreciation & Amortization | 489.00M | 422.00M | 378.00M | 289.00M | 253.70M | 228.60M | 190.10M | 146.50M | 140.60M | 140.80M | 142.90M | 152.20M | 129.70M | 115.50M |
EBITDA | -284.00M | 266.00M | 1.08B | 1.11B | 640.20M | 499.80M | 453.50M | 372.20M | 374.00M | 358.30M | 373.40M | 309.90M | 305.10M | 275.60M |
EBITDA Ratio | -6.48% | 1.85% | 15.06% | 16.08% | 12.85% | 11.53% | 11.46% | 11.73% | 13.26% | 12.87% | 13.86% | 19.72% | 20.82% | 19.04% |
Operating Income | -749.00M | -137.00M | 349.00M | 354.00M | 143.80M | 61.80M | 271.10M | 234.20M | 217.80M | 259.90M | 240.90M | 204.40M | 198.00M | 186.10M |
Operating Income Ratio | -17.10% | -3.20% | 7.23% | 8.85% | 4.65% | 2.45% | 11.01% | 11.28% | 11.79% | 14.20% | 13.18% | 11.35% | 11.68% | 12.15% |
Total Other Income/Expenses | -278.00M | -179.00M | -151.00M | -113.00M | -133.60M | -113.70M | -119.10M | -98.60M | -72.90M | -147.40M | -173.50M | -228.30M | -179.40M | -191.50M |
Income Before Tax | -1.03B | -315.00M | 605.00M | 715.00M | 260.40M | 160.30M | 152.00M | 135.60M | 144.90M | 112.50M | 67.40M | -23.90M | 18.60M | -5.40M |
Income Before Tax Ratio | -23.44% | -7.37% | 12.53% | 17.88% | 8.42% | 6.37% | 6.17% | 6.53% | 7.84% | 6.14% | 3.69% | -1.33% | 1.10% | -0.35% |
Income Tax Expense | 16.00M | -83.00M | 86.00M | 130.00M | 39.70M | 22.90M | 68.40M | 25.80M | 33.70M | -97.70M | 49.50M | 24.10M | 500.00K | 23.70M |
Net Income | -1.04B | -232.00M | 499.00M | 585.00M | 173.00M | 137.40M | 83.60M | 109.80M | 111.50M | 212.20M | 16.20M | -46.70M | -24.40M | -54.00M |
Net Income Ratio | -23.81% | -5.43% | 10.34% | 14.63% | 5.59% | 5.46% | 3.39% | 5.29% | 6.03% | 11.59% | 0.89% | -2.59% | -1.44% | -3.53% |
EPS | -5.76 | -1.28 | 2.74 | 3.15 | 1.15 | 0.95 | 0.64 | 0.88 | 0.89 | 1.77 | 0.14 | -0.40 | -0.21 | -0.46 |
EPS Diluted | -5.76 | -1.28 | 2.71 | 3.11 | 1.14 | 0.94 | 0.63 | 0.87 | 0.89 | 1.75 | 0.14 | -0.40 | -0.21 | -0.46 |
Weighted Avg Shares Out | 181.00M | 181.00M | 176.00M | 168.00M | 149.79M | 144.25M | 131.20M | 125.00M | 124.80M | 119.89M | 117.30M | 117.32M | 117.32M | 117.32M |
Weighted Avg Shares Out (Dil) | 181.00M | 181.00M | 178.00M | 170.00M | 152.32M | 145.95M | 133.20M | 126.70M | 125.90M | 121.30M | 117.30M | 117.32M | 117.32M | 117.32M |
CATALENT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalent, Inc. - CTLT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. - CTLT
S&P 500's surge to new highs: Bull trap hiding in plain sight?
Wegovy packing supplier Catalent lays off 300 workers
Catalent (CTLT) Q2 Earnings Lag Estimates, Gross Margin Down
Catalent (CTLT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Catalent Q2 sales inch past estimates amid takeover by Novo Holdings
Catalent, Inc. Reports Second Quarter Fiscal 2024 Results
Can financial, healthcare, energy stocks rise as rates stay high?
Astrazeneca says Catalent deal shows importance of in-house capacity
Source: https://incomestatements.info
Category: Stock Reports